Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500234 | 1.00 | TACR1 (0.47) | TACR1HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL4985979 | 1.00 | TACR1 (0.47) | TACR1HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL13476404 | 0.76 | KDM1A (0.34) | KDM1AHDAC2 | |
| SCHEMBL13476763 | 0.76 | KDM1A (0.34) | KDM1AHDAC2 | |
| SCHEMBL16422679 | 0.75 | HTR2C (0.41) | TACR1HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL27669161 | 0.71 | HTR2C (0.44) | TACR1HTR2CHTR2AHTR2BKDM1A | |
| SCHEMBL6955904 | 0.70 | FUCA1 (0.44) | TACR1HTR2CHTR2AKDM1APAX8 | |
| SCHEMBL5989023 | 0.70 | TACR1 (0.44) | TACR1PAX8 | |
| SCHEMBL3180166 | 0.70 | TACR1 (0.44) | TACR1PAX8 | |
| SCHEMBL3172844 | 0.70 | TACR1 (0.44) | TACR1PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645790-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-11-13 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1711465-B1 | HYDROISOINDOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
| US-7217731-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165083-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885HTR2C 71/4885HTR2A 65/4885 |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885HTR2C 71/4885HTR2A 65/4885 |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885HTR2C 65/4885HTR2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.